Core Insights - On December 1, a total of 34 stocks appeared on the trading leaderboard, with 16 showing net institutional buying and 18 showing net selling [2] - The top three stocks with the highest net institutional buying were Beijing Junzheng, Guangqi Technology, and Guangji Pharmaceutical, with net buying amounts of 251 million, 147 million, and 77 million respectively [2][3] - The top three stocks with the highest net institutional selling were Haike Xinyuan, Jereh, and Guanghe Tong, with net selling amounts of 142 million, 128 million, and 85 million respectively [2][4] Institutional Buying Summary - Beijing Junzheng had a price increase of 20.00% with a net institutional buying of 250.78 million [3] - Guangqi Technology saw a price increase of 10.01% with a net institutional buying of 147.07 million [3] - Guangji Pharmaceutical experienced a price increase of 3.09% with a net institutional buying of 77.21 million [3] Institutional Selling Summary - Haike Xinyuan had a price decrease of 5.63% with a net institutional selling of 141.86 million [4] - Jereh saw a price increase of 9.99% with a net institutional selling of 128.42 million [4] - Guanghe Tong experienced a price increase of 20.01% with a net institutional selling of 85.12 million [4]

Summary of Key Points Core Viewpoint - On December 1, a total of 34 stocks were identified with institutional activity, with 16 stocks showing net buying and 18 stocks showing net selling by institutions [1] Institutional Buying - The top three stocks with the highest net buying by institutions were: - Beijing Junzheng with a net buying amount of 251 million [1] - Guangqi Technology with a net buying amount of 147 million [1] - Guangji Pharmaceutical with a net buying amount of 77.21 million [1] Institutional Selling - The top three stocks with the highest net selling by institutions were: - Haike Xinyuan with a net outflow amount of 142 million [1] - Jereh with a net outflow amount of 128 million [1] - Guanghetong with a net outflow amount of 85.12 million [1]

Core Insights - On December 1, a total of 34 stocks were involved with institutional investors, with 16 showing net buying and 18 showing net selling [1] - The top three stocks with net buying by institutions were Beijing Junzheng, Guangqi Technology, and Guangji Pharmaceutical, with net buying amounts of 251 million, 147 million, and 77 million respectively [1][2] - The top three stocks with net selling by institutions were Haike Xinyuan, Jereh Holdings, and Guanghetong, with net selling amounts of 142 million, 128 million, and 85 million respectively [1][3] Institutional Buying Summary - Beijing Junzheng had a price increase of 20.00% with a net buying of 250.78 million [2] - Guangqi Technology saw a price increase of 10.01% with a net buying of 147.07 million [2] - Guangji Pharmaceutical experienced a price increase of 3.09% with a net buying of 77.21 million [2] - Other notable stocks with institutional buying included Pengding Holdings (9.99%, 61.64 million) and Kexiang Technology (20.00%, 50.83 million) [2] Institutional Selling Summary - Haike Xinyuan had a price decrease of 5.63% with a net selling of 141.86 million [3] - Jereh Holdings experienced a price decrease of 7.66% with a net selling of 128.00 million [3] - Guanghetong saw a price increase of 20.01% but had a net selling of 85.12 million [3] - Other significant stocks with institutional selling included Huabao Holdings (9.99%, 128.42 million) and Zhongxing Communications (10.00%, 53.03 million) [3]

Market Overview - The chemical pharmaceutical sector increased by 0.16% on December 1, with Changshan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Chemical Pharmaceutical Sector - Changshan Pharmaceutical (300255) closed at 67.70, up 8.93% with a trading volume of 353,700 shares and a transaction value of 2.379 billion [1] - Laimei Pharmaceutical (300006) closed at 5.42, up 5.24% with a trading volume of 821,100 shares [1] - Oukang Pharmaceutical (920230) closed at 13.22, up 3.44% with a trading volume of 11,400 shares [1] Top Losers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 27.05, down 8.24% with a trading volume of 315,300 shares [2] - Keyuan Pharmaceutical (301281) closed at 27.96, down 4.51% with a trading volume of 44,300 shares [2] - Kangzhiyue Pharmaceutical (300086) closed at 12.17, down 4.32% with a trading volume of 864,700 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 1.011 billion from institutional investors, while retail investors saw a net inflow of 466 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Maiwei Bio (688062) had a net inflow of 48.528 million from institutional investors, but a net outflow of 65.659 million from retail investors [3] - Lijun Group (000513) saw a net inflow of 23.529 million from institutional investors, with a net outflow of 25.007 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 18.642 million from institutional investors, while retail investors experienced a net inflow of 10.459 million [3]

Group 1 - The core point of the news is that Guangji Pharmaceutical's stock price increased by 5.22% to 9.87 CNY per share, with a trading volume of 635 million CNY and a turnover rate of 20.39%, resulting in a total market capitalization of 3.422 billion CNY [1] - Guangji Pharmaceutical, established on May 28, 1993, and listed on November 12, 1999, is located in Wuxue City, Hubei Province. The company specializes in the production and sales of pharmaceutical raw materials, veterinary raw materials, feed additives, and fine chemical products [1] - The revenue composition of Guangji Pharmaceutical includes 74.56% from raw material products, 22.97% from formulation products, 1.45% from other products, and 1.02% from supplementary sources [1] Group 2 - Among the top ten circulating shareholders of Guangji Pharmaceutical, one fund from Huaxia Fund, the Huaxia CSI 500 Index Enhanced A (007994), has recently entered the list, holding 2.2814 million shares, which accounts for 0.66% of the circulating shares [2] - The Huaxia CSI 500 Index Enhanced A fund was established on March 25, 2020, with a latest scale of 3.308 billion CNY. It has achieved a year-to-date return of 24.47%, ranking 1946 out of 4207 in its category, and a one-year return of 24.63%, ranking 1851 out of 4009 [2] - The fund manager of Huaxia CSI 500 Index Enhanced A is Sun Meng, who has been in the position for 5 years and 261 days, managing a total fund size of 16.118 billion CNY. During his tenure, the best fund return was 131.64%, while the worst was 20.71% [3]

Group 1 - The flu-related concept has become active again, with Haiwang Bio hitting the daily limit up [2] - Yue Wannianqing has increased by over 12% [2] - Other companies such as Guangji Pharmaceutical, Hendi Pharmaceutical, Te Yi Pharmaceutical, Jinshi Yiyao, and Xinhua Pharmaceutical have also seen gains [2]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Group 1 - The vitamin sector experienced a decline of 0.39%, ranking among the top losers in the concept sector, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the daily limit down [1][2] - Notable gainers in the vitamin sector included Haiwang Biological, *ST Zhongji, and Zhenhua Co., which rose by 10.03%, 5.01%, and 4.99% respectively [1][4] - The vitamin sector saw a net outflow of 706 million yuan from major funds, with 43 stocks experiencing net outflows, and 10 stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - The top net outflow stock was Zhongsheng Pharmaceutical, with a net outflow of 684 million yuan, followed by Xinhua Pharmaceutical and Guangji Pharmaceutical with net outflows of 58.33 million yuan and 50.49 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflow included Haiwang Biological, Zhenhua Co., and Xinhecheng, with net inflows of 145 million yuan, 67.37 million yuan, and 24.76 million yuan respectively [2][4] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78% despite a price drop of 10% [3][4]

Group 1 - The flu concept sector declined by 0.49%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the flu concept sector that saw significant declines include Zhongsheng Pharmaceutical (-10.00%), Guangji Pharmaceutical (-9.98%), and Hainan Haiyao (+2.34%) [2][3] - The flu concept sector experienced a net outflow of 1.24 billion yuan, with Zhongsheng Pharmaceutical leading the outflow at 684 million yuan [2][3] Group 2 - The top gainers in the flu concept sector included Haiwang Biological (+10.03%), Baihua Pharmaceutical (+10.01%), and Tailong Pharmaceutical (+5.37%) [1][7] - The overall market saw a mixed performance, with 63 stocks in the flu concept sector rising while others fell significantly [1][2] - The concept sectors with the highest gains included Titanium Dioxide (+4.31%) and Hainan Free Trade Zone (+3.54%), contrasting with the flu concept sector's decline [2]

Group 1 - The hepatitis concept sector declined by 0.31%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the hepatitis sector that saw significant outflows include Zhongsheng Pharmaceutical with a net outflow of 684 million yuan, followed by Te Yi Pharmaceutical and Pian Zai Huang with net outflows of 112 million yuan and 81 million yuan respectively [2][3] - Conversely, stocks that experienced net inflows include Baihua Pharmaceutical, Huadong Medicine, and Kangzhi Pharmaceutical, with inflows of 97.75 million yuan, 43.11 million yuan, and 21.20 million yuan respectively [6] Group 2 - The top gainers in the hepatitis sector included Baihua Pharmaceutical, which rose by 10.01%, followed by Chengda Pharmaceutical and Kangzhi Pharmaceutical with increases of 4.79% and 3.00% respectively [1][6] - The overall market sentiment for the hepatitis sector appears negative, as evidenced by the significant net outflows and the number of stocks declining in value [2][3] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78%, indicating active trading despite the price drop [2][3]